A Phase 3 Randomized Trial of the Safety and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults ≥ 60 Years of Age in Japan, South Korea, and Taiwan.
Vaccine（2024）
Key words
Asian,20-valent pneumococcal conjugate vaccine,Streptococcus pneumoniae,Immunogenicity,Safety,Clinical study
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined